Symptomatic Severe Bradycardia during Pazopanib Treatment Pazopanib Tedavisi Sırasında Semptomatik Şiddetli Bradikardi

ZORKUN C. S., Eren Ö. A.

Turk Kardiyoloji Dernegi Arsivi, vol.53, no.2, pp.140-142, 2025 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 53 Issue: 2
  • Publication Date: 2025
  • Doi Number: 10.5543/tkda.2024.03788
  • Journal Name: Turk Kardiyoloji Dernegi Arsivi
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Central & Eastern European Academic Source (CEEAS), Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.140-142
  • Keywords: Angiosarcoma, cardiotoxicity, pazopanib, permissive cardiotoxicity
  • Istanbul University Affiliated: Yes

Abstract

Pazopanib, a tyrosine kinase inhibitor that targets growth factor receptors, is associated with various side effects, including bradycardia. We report a severe case of symptomatic bradycardia, with a heart rate dropping to 28 beats per minute, in a patient with cardiac angiosarcoma treated with 800 mg/day of pazopanib. Reducing the dosage to 600 mg/day improved the heart rate to 53 beats per minute. This case highlights the risk of severe bradycardia associated with pazopanib, emphasizing the need for vigilant heart rate monitoring.